Shorla Oncology at BioEquity Europe 2023 in DublinMay 16th 2023Read More Shorla Oncology at BioEquity Europe 2023 in Dublin
Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine InjectionMay 16th 2023Read More Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection
Shorla Oncology will be attending Asembia’s ASX Summit in Las VegasApril 17th 2023Read More Shorla Oncology will be attending Asembia’s ASX Summit in Las Vegas
FDA Approves Nelarabine Injection for T-cell Leukemia and LymphomaMarch 27th 2023Read More FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma
Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023March 23rd 2023Read More Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023
US FDA approves Shorla’s oncology drug for T-cell leukaemiaMarch 20th 2023Read More US FDA approves Shorla’s oncology drug for T-cell leukaemia
Shorla wins FDA approval for leukaemia drugMarch 20th 2023Read More Shorla wins FDA approval for leukaemia drug
Irish-founded Shorla Oncology secures FDA approval for leukaemia drugMarch 9th 2023Read More Irish-founded Shorla Oncology secures FDA approval for leukaemia drug
